AI Drug Discovery for Pharma and Biotech

Drug discovery

35

papers

On emerging therapies

Overview

22q11.2 Duplication Syndrome Clinical Overview
A rare chromosomal disorder caused by a 3 Mb microduplication at chromosome 22q11.2, characterized by extreme phenotypic variability. Common features include developmental delay (67%), intellectual disability (97%), hypotonia (43%), and growth retardation (63%) [1][6][7]. Congenital anomalies (cardiac, urogenital, cleft palate) and neuropsychiatric disorders (ADHD, autism spectrum disorder) occur more frequently than in the general population [7][9][13]. Approximately 70% of cases are inherited, often from minimally symptomatic parents [1][6].

Population

  • Estimated prevalence of 1:1,606 in population-based studies [2][17], rising to 1:700 in high-risk cohorts (e.g., intellectual disability referrals) [7][16].

  • 70% inherited; ~30% de novo [1][18].

Burden

  • 10% develop ADHD, autism, or intellectual disability by age 32 [2]; higher neuropsychiatric morbidity vs. deletions [2][13].

  • Lifetime healthcare utilization: 60% require interventions for congenital anomalies; 25% need long-term developmental support [7][12][16].

Therapies

  • Multidisciplinary care: Cardiac surgery for congenital defects, speech/occupational therapy, and psychiatric management for ADHD/autism [6][12][18].

  • Routine screenings: Developmental assessments, calcium monitoring (for hypoparathyroidism), and neuropsychiatric evaluations [3][12][18].

Categories: rare developmental anomalies during embryogenesis, rare genetic diseases

Research Papers

35 drug discovery papers about 22q11.2 duplication syndrome. Recent publications:

35 drug discovery papers about 22q11.2 duplication syndrome. Recent publications:

categories:

Small molecules

small molecules
2026-06-01 | Neuropsychiatric Psychosis and Xanomeline in the treatment of an Adolescent with a MED13L mutation

Introduction The Mediator complex is a 26 gene multi-subunit transcriptional regulator essential for RNA polymerase II-mediated gene expression in humans. Mediator complex mutations cause Lujan and Cornelia de Lange syndrome. More specifically, MED13L mutations cause neurodevelopmental disorders with structural brain abnormalities, intellectual disability and autism. Reports of psychosis in MED13L variants are not common while treatment strategies are unmapped. Objectives A report is undertaken of the therapeutic potential of xanomeline to ameliorate psychotic symptoms in a treatment-resistant adolescent with a MED13L mutation. Methods Use of xanomeline is detailed in a 15-year-old male harboring a heterozygous de novo missense MED13L variant (c.3410 A>G, p.N1137S) and a 22q11.2 duplication copy number variant. Results A 15 year-old male with a MED13L deleterious point mutation presented with worsening of psychotic symptoms, and a diagnosis of schizoaffective disorder, bipolar type. Past psychiatric history was notable for prior hospitalizations in May and April 2024 for aggression, in December 2024 for aggression and suicidal ideation and in July 2025 for aggression. Prior trials include citalopram 10 mg (worsened agitation), aripiprazole 5 mg (ineffective), haloperidol 7.5 mg (ineffective), olanzapine 10 mg (ineffective), valproate 750 mg (tremors, weight gain), sertraline (worsening manic symptoms) in 2024 and Ativan 1 mg TID (disinhibition) in 2023. Given the poor response overall to various mood-stabilizing and antipsychotic medications, xanomeline at 50 mg (+ 20 mg trospium) twice daily, titrated to 100/20 mg twice daily was cross-tapered with risperidone. Over the next 2 weeks, the patient’s behavior improved, he was more social and no more aggressive episodes were evident. No significant side effects were noted from use of xanomeline. Conclusions Xanomeline-trospium is an antipsychotic recently approved by FDA in September 2024 for use in adults with schizophrenia. Xanomeline, a muscarinic M1/M4 agonist, is given in combination with trospium to minimize GI side effects. In our patient, the drug was well tolerated and produced positive effects on psychosis and aggression in a span of 2 weeks. Unlike most antipsychotic agents, xanomeline does not exert any effect on dopamine or serotonin receptors. Most common adverse reactions include GI symptoms such as nausea, dyspepsia. Genetic variants presenting with psychotic symptoms include the 22q11 microdeletion syndrome, Prader-Willi syndrome among others. Due to the organic brain dysfunction that these syndromes entail, psychotic syndromes can follow a torpid course with limited response to current treatment options. This report considers the use of the novel low-side effect profile xanomeline-trospium for the treatment of psychosis in genetic syndromes which can be more susceptible to side effects. Disclosure of Interest None Declared

Open article ↗



2024-02-20 | Neurovascular mitochondrial susceptibility impacts blood-brain barrier function and behavior

Abstract Maintenance of blood-brain barrier (BBB) integrity is critical to optimal brain function, and its impairment has been linked to multiple neurological disorders. A notable feature of the BBB is its elevated mitochondrial content compared to peripheral endothelial cells, although the functional implications of this phenomenon remain unknown. Here we studied BBB mitochondrial function in the context of the 22q11.2 deletion syndrome (22qDS), a condition associated with a highly increased risk for neuropsychiatric disease. As the 22q11.2 deletion includes 6 mitochondrial genes, and because we have previously identified BBB impairment in 22qDS, we addressed the hypothesis that mitochondrial deficits contribute to BBB dysfunction and impact behavior in this condition. We report mitochondrial impairment in human induced pluripotent stem cell (iPSC)-derived BBB endothelial cells from 22qDS patients, and in BBB endothelial cells from a mouse model of 22qDS. Remarkably, treatment to improve mitochondrial function attenuates mitochondrial deficits and enhances BBB function in both the iPSC and mouse 22qDS models. This treatment also corrected social memory in the mouse model, a deficit previously associated with BBB dysfunction. As BBB integrity correlated with social memory performance, together our findings suggest that mitochondrial dysfunction in the BBB influences barrier integrity and behavior in 22qDS.

Open article ↗



2021-05-19 | Association of Mitochondrial Biogenesis With Variable Penetrance of Schizophrenia

Discovery of mechanisms that underlie variable penetrance for neuropsychiatric illness in the context of genetic variants that carry elevated risk can advance novel treatment approaches for these disorders.To test the hypothesis that mitochondrial compensation is associated with the variable penetrance of schizophrenia in the 22q11.2 deletion syndrome (22q11DS).This case-control study compared measures of mitochondrial function and the expression of related genes in 14 induced pluripotent stem cell-derived neurons from typically developing control individuals (6 lines) and from adults with 22q11DS (8 lines). The individuals with 22q11DS included 2 groups, those carrying a diagnosis of schizophrenia and those without this diagnosis (4 lines each). Similar measures were made of lymphoblastic cells lines (LCLs) from a separate group of adults with 22q11DS with (10 lines) or without (8 lines) schizophrenia. The study included samples derived from a clinical setting. The induced pluripotent stem cell lines were derived from individuals with 22q11DS with or without a diagnosis of schizophrenia at Stanford University. The LCLs were from adults within the 22q and You Center at the Children's Hospital of Philadelphia. Data were analyzed between July 1, 2019, and January 24, 2021.Total adenosine triphosphate (ATP), oxidative phosphorylation (OXPHOS) complex activity, and messenger RNA expression via reverse transcription-polymerase chain reaction of selected genes encoding for mitochondrial proteins.Study participants included men and women aged 18 to 37 years. Of 32 participants, the mean (SD) age of men was 27 (1.9) years and of women was 29 (1.2) years. Replicating a previous study, neurons from the 22q11DS and schizophrenia (22q+Sz) group had reduced ATP levels (mean [SD], 15.6 [1.5] vs 21.9 [1.4]; P = .02) and reduced OXPHOS activity (ie, complex I; 1.51 [0.1] vs 1.89 [0.1]; P = .01). These deficits were not present in neurons from individuals with 22q11DS without schizophrenia (22q[-]Sz). In this group, the expression of multiple genes encoding OXPHOS subunits was significantly upregulated. For example, compared with control individuals, NDUFV2 expression was increased by 50% in the 22q(-)Sz group (P < .001) but not significantly changed in the 22q+Sz group. Expression of genes driving mitochondrial biogenesis, including PGC1α, showed a similar pattern of upregulation in the 22q(-)Sz group compared with the control and the 22q+Sz groups. Stimulation of mitochondrial biogenesis normalizes the ATP deficit seen in 22q+Sz neurons. Finally, using LCLs from a separate group of adults with 22q11DS, evidence for enhanced mitochondrial biogenesis was again found in the 22q(-)Sz group.In this study, an increase in mitochondrial biogenesis and function was associated with the absence of schizophrenia in neurons and LCLs from individuals with 22q11DS, but the deficit in the 22q+Sz group was reversible by agents that enhance mitochondrial biogenesis. Enhancement of mitochondrial biogenesis may provide a targetable opportunity for treatment or prevention of this disorder in individuals with 22q11DS.

Open article ↗



2021-05-12 | Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study

Abstract Dopaminergic dysregulation is one of the leading hypotheses for the pathoetiology underlying psychotic disorders such as schizophrenia. Molecular imaging studies have shown increased striatal dopamine synthesis capacity (DSC) in schizophrenia and people in the prodrome of psychosis. However, it is unclear if genetic risk for psychosis is associated with altered DSC. To investigate this, we recruited healthy controls and two antipsychotic naive groups of individuals with copy number variants, one with a genetic deletion at chromosome 22q11.2, and the other with a duplication at the same locus, who are at increased and decreased risk for psychosis, respectively. Fifty-nine individuals (21 with 22q11.2 deletion, 12 with the reciprocal duplication and 26 healthy controls) received clinical measures and [18F]-DOPA PET imaging to index striatal Ki cer . There was an inverse linear effect of copy number variant number on striatal Ki cer value ( B = −1.2 × 10 −3 , SE = 2 × 10 −4 , p < 0.001), with controls showing levels intermediate between the two variant groups. Striatal Ki cer was significantly higher in the 22q11.2 deletion group compared to the healthy control ( p < 0.001, Cohen’s d = 1.44) and 22q11.2 duplication ( p < 0.001, Cohen’s d = 2) groups. Moreover, Ki cer was positively correlated with the severity of psychosis-risk symptoms ( B = 730.5, SE = 310.2, p < 0.05) and increased over time in the subject who went on to develop psychosis, but was not associated with anxiety or depressive symptoms. Our findings suggest that genetic risk for psychosis is associated with dopaminergic dysfunction and identify dopamine synthesis as a potential target for treatment or prevention of psychosis in 22q11.2 deletion carriers.

Open article ↗



2019-05-28 | Modeling and Predicting Developmental Trajectories of Neuropsychiatric Dimensions Associated With Copy Number Variations

Abstract Copy number variants, such as duplications and hemizygous deletions at chromosomal loci of up to a few million base pairs, are highly associated with psychiatric disorders. Hemizygous deletions at human chromosome 22q11.2 were found to be associated with elevated instances of schizophrenia and autism spectrum disorder in 1992 and 2002, respectively. Following these discoveries, many mouse models have been developed and tested to analyze the effects of gene dose alterations in small chromosomal segments and single genes of 22q11.2. Despite several limitations to modeling mental illness in mice, mouse models have identified several genes on 22q11.2—Tbx1, Dgcr8, Comt, Sept5, and Prodh—that contribute to dimensions of autism spectrum disorder and schizophrenia, including working memory, social communication and interaction, and sensorimotor gating. Mouse studies have identified that heterozygous deletion of Tbx1 results in defective social communication during the neonatal period and social interaction deficits during adolescence/adulthood. Overexpression of Tbx1 or Comt in adult neural progenitor cells in the hippocampus delays the developmental maturation of working memory capacity. Collectively, mouse models of variants of these 4 genes have revealed several potential neuronal mechanisms underlying various aspects of psychiatric disorders, including adult neurogenesis, microRNA processing, catecholamine metabolism, and synaptic transmission. The validity of the mouse data would be ultimately tested when therapies or drugs based on such potential mechanisms are applied to humans.

Open article ↗



oligonucleotides
2026-06-01 | Chromosomal abnormalities and pregnancy outcomes in 350 pregnancies with prenatally diagnosed aberrant right subclavian artery: a phenotype-based retrospective cohort study

Aberrant right subclavian artery (ARSA) is the most frequent aortic-arch branching variant on prenatal sonography, and its clinical relevance is governed by the phenotypic context in which it is detected. Genotype–phenotype interpretation remains complicated by uneven genetic testing uptake and the additional anomaly burden carried in non-isolated cases. This retrospective single-center cohort comprised 350 singleton pregnancies in which ARSA was diagnosed prenatally at a tertiary perinatology center between January 2020 and April 2025. Cases were classified as isolated ARSA (n = 200), ARSA with soft markers (n = 80), or non-isolated ARSA (n = 70). The primary outcome was chromosomal abnormalities, reported with explicit denominator separation: whole-cohort prevalence and diagnostic yield among invasively tested fetuses. The 22q11.2 deletion case definition required dual confirmation by FISH and chromosomal microarray analysis (CMA). Marker- and anomaly-specific yields were examined to identify findings most strongly linked to chromosomal and adverse pregnancy outcomes. Genetic evaluation acceptance varied by phenotype (75.0% isolated, 92.5% soft markers, 92.9% non-isolated; p < 0.001). Whole-cohort chromosomal-abnormality prevalence was 4.5%, 17.5%, and 32.9%; diagnostic yield among invasively tested fetuses was 6.0%, 18.9%, and 35.4%. Trisomy 21 was the most frequent abnormality across phenotypes. Five 22q11.2 deletions (1/1/3 across phenotypes) fulfilled the dual-confirmation criteria; all three non-isolated 22q11.2 cases harbored a conotruncal cardiac anomaly. Marker co-occurrence (≥2 markers, 43.8% of soft-markers) and concurrent major anomalies (≥2, 44.3% of non-isolated) drove yield. Live-birth rates were 97.5%, 87.5%, and 71.4% (p < 0.001). On multivariable logistic regression, ARSA with soft markers (adjusted OR 4.52; 95% CI 1.86–10.96) and non-isolated ARSA (adjusted OR 10.51; 95% CI 4.52–24.44) remained independent predictors of chromosomal abnormality (optimism-corrected AUC 0.708). A compound phenotype (major anomaly + ≥2 soft markers) was present in 25.7% of non-isolated fetuses. Phenotype-based classification of prenatal ARSA reveals a significant risk gradient for chromosomal abnormality and adverse pregnancy outcome, with co-occurring markers and conotruncal anomalies emerging as the strongest individual signals. The findings support risk-concordant counseling: conservative invasive testing in confirmed isolated ARSA, intensified evaluation when soft markers co-occur, and a compound-phenotype-aware, anatomy-directed approach, including CMA and 22q11.2-targeted testing for conotruncal lesions, in the non-isolated subgroup.

Open article ↗



2025-05-27 | An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome.

Adults and children with the 22q11.2 Deletion Syndrome demonstrate cognitive, social, and emotional impairments and high risk for schizophrenia. Work in mouse model of the 22q11.2 deletion provided compelling evidence for abnormal expression and processing of microRNAs. A major transcriptional effect of the microRNA dysregulation is upregulation of Emc10, a component of the ER membrane complex, which promotes membrane insertion of a subset of polytopic and tail-anchored membrane proteins. We previously uncovered a key contribution of EMC10 in mediating the behavioral phenotypes observed in 22q11.2 deletion mouse models. Here, we show that expression and processing of miRNAs is abnormal and EMC10 expression is elevated in neurons derived from 22q11.2 deletion carriers. Reduction of EMC10 levels restores defects in neurite outgrowth and calcium signaling in patient neurons. Furthermore, antisense oligonucleotide administration and normalization of Emc10 in the adult mouse brain not only alleviates cognitive deficits in social and spatial memory but remarkably sustains these improvements for over 2 months post-injection, indicating its therapeutic potential. Broadly, our study integrates findings from both animal models and human neurons to elucidate the translational potential of modulating EMC10 levels and downstream targets as a specific venue to ameliorate disease progression in 22q11.2 Deletion Syndrome.

Open article ↗



2024-05-03 | DGCR8 haploinsufficiency leads to primate-specific RNA dysregulation and pluripotency defects

The 22q11.2 deletion syndrome (22qDS) is caused by a microdeletion in chromosome 22, including DGCR8, an essential gene for miRNA production. The contribution of human DGCR8 hemizygosity to the disease is still unclear. In this study, we generated two human pluripotent cell models containing a single functional DGCR8 allele to elucidate its role on 22qDS. DGCR8+/- cells show increased apoptosis as well as self-renewal and differentiation defects in both the naive and primed states. The expression of primate-specific miRNAs was largely affected, due to impaired miRNA processing and chromatin accessibility. DGCR8+/- cells also displayed a pronounced reduction in human endogenous retrovirus class H (HERVH) expression, a primate-specific retroelement essential for pluripotency maintenance. Importantly, the reintroduction of primate-specific miRNAs as well as the miR-371-3 cluster rescued the cellular and molecular phenotypes of DGCR8+/- cells. Our results suggest that DGCR8 is haploinsufficient in humans and that miRNAs and transposable elements may have co-evolved in primates as part of an essential regulatory network to maintain stem cell identity.

Open article ↗



2024-01-21 | 194 Fetal fraction amplification dramatically increases PPV for 22q11.2 deletion syndrome in prenatal cell-free DNA screening

22q11.2 deletion syndrome occurs in approximately 1 in 2,000-4,000 births. Prenatal cell-free DNA screening (pcfDNA) can detect fetuses affected by deletions as small as 2.5 Mb. Fetal fraction amplification (FFA), which has been shown to yield an average fetal fraction (FF) in excess of 20%, may further enhance pcfDNA detection of these deletions. Positive predictive values (PPV) of pcfDNA screening for 22q11.2 microdeletion have been reported between 20%-50%. Here, we sought to describe the impact of FFA on the PPV of 22q11.2 microdeletion screening using a whole-genome sequencing (WGS)-based pcfDNA platform. We retrospectively analyzed data from patients who underwent WGS-based pcfDNA screening with FFA (Prequel™, Myriad Genetics, Inc.) between 8/20-10/22. For screen-positive cases, pregnancy outcome data were requested via a routine HIPAA-compliant process. All samples with diagnostic confirmation were used to calculate PPV, defined as: true positives/(true positives + false positives). Confidence interval (CI) was estimated using the Exact Binomial Test. Complete outcomes were obtained for 54 cases that screened positive for 22q11.2 microdeletion; 21 underwent molecular diagnostic testing. All 21 were confirmed as true positives, for a PPV of 100% (21/21; 95% CI 83.9%-100%). Among the 33 cases that declined molecular confirmation, 17 had ultrasound findings that are either strongly or moderately associated with 22q11.2 deletion syndrome (e.g., cardiac defects, polyhydramnios, skeletal defects, intrauterine growth restriction). The average FF of true positive samples was 23.0%. For screen-positive patients who declined diagnostic testing, the average FF was 21.6%. The increased FF levels conferred by FFA yield a PPV for 22q11.2 microdeletion higher than any previous studies have reported, and comparable to that for common autosomal trisomies. Because respective FF levels were comparable in patients with and without diagnostic confirmation, PPV is likely to be comparable in patients with and without diagnostic confirmation.

Open article ↗



2021-05-10 | Long Noncoding RNA lnc-TSSK2-8 Activates Canonical Wnt/β-Catenin Signaling Through Small Heat Shock Proteins HSPA6 and CRYAB

Congenital heart defects (CHDs) are the most common birth defects worldwide. 22q11.2 deletion syndrome is the most common microdeletion disorder that has been frequently associated with conotruncal malformations. By now, the dosage-sensitive gene TBX1 has been adopted as the major pathogenic gene responsible for 22q11.2 deletion, which is regulated by canonical Wnt/β-catenin signaling pathway in heart outflow tract development. Here, we report the long noncoding RNA (lncRNA) lnc-TSSK2-8, which is encompassed in the 22q11.2 region, that can activate canonical Wnt/β-catenin signaling by protecting β-catenin from degradation, which could result from decreased ubiquitination. Such effects were mediated by two short heat shock proteins HSPA6 and α-β-crystallin (CRYAB), whose expression was regulated by lnc-TSSK2-8 through a competing endogenous RNA (ceRNA) mechanism. In clinical practice, the pathogenesis of copy number variation (CNV) was always attributed to haploinsufficiency of protein-coding genes. Here, we report that the 22q11.2 lncRNA lnc-TSSK2-8 significantly activated canonical Wnt/β-catenin signaling, which has major roles in cardiac outflow tract development and should act upstream of TBX1. Our results suggested that lncRNAs should contribute to the etiology of CNV-related CHD.

Open article ↗



small molecules
2026-06-01 | Neuropsychiatric Psychosis and Xanomeline in the treatment of an Adolescent with a MED13L mutation

Introduction The Mediator complex is a 26 gene multi-subunit transcriptional regulator essential for RNA polymerase II-mediated gene expression in humans. Mediator complex mutations cause Lujan and Cornelia de Lange syndrome. More specifically, MED13L mutations cause neurodevelopmental disorders with structural brain abnormalities, intellectual disability and autism. Reports of psychosis in MED13L variants are not common while treatment strategies are unmapped. Objectives A report is undertaken of the therapeutic potential of xanomeline to ameliorate psychotic symptoms in a treatment-resistant adolescent with a MED13L mutation. Methods Use of xanomeline is detailed in a 15-year-old male harboring a heterozygous de novo missense MED13L variant (c.3410 A>G, p.N1137S) and a 22q11.2 duplication copy number variant. Results A 15 year-old male with a MED13L deleterious point mutation presented with worsening of psychotic symptoms, and a diagnosis of schizoaffective disorder, bipolar type. Past psychiatric history was notable for prior hospitalizations in May and April 2024 for aggression, in December 2024 for aggression and suicidal ideation and in July 2025 for aggression. Prior trials include citalopram 10 mg (worsened agitation), aripiprazole 5 mg (ineffective), haloperidol 7.5 mg (ineffective), olanzapine 10 mg (ineffective), valproate 750 mg (tremors, weight gain), sertraline (worsening manic symptoms) in 2024 and Ativan 1 mg TID (disinhibition) in 2023. Given the poor response overall to various mood-stabilizing and antipsychotic medications, xanomeline at 50 mg (+ 20 mg trospium) twice daily, titrated to 100/20 mg twice daily was cross-tapered with risperidone. Over the next 2 weeks, the patient’s behavior improved, he was more social and no more aggressive episodes were evident. No significant side effects were noted from use of xanomeline. Conclusions Xanomeline-trospium is an antipsychotic recently approved by FDA in September 2024 for use in adults with schizophrenia. Xanomeline, a muscarinic M1/M4 agonist, is given in combination with trospium to minimize GI side effects. In our patient, the drug was well tolerated and produced positive effects on psychosis and aggression in a span of 2 weeks. Unlike most antipsychotic agents, xanomeline does not exert any effect on dopamine or serotonin receptors. Most common adverse reactions include GI symptoms such as nausea, dyspepsia. Genetic variants presenting with psychotic symptoms include the 22q11 microdeletion syndrome, Prader-Willi syndrome among others. Due to the organic brain dysfunction that these syndromes entail, psychotic syndromes can follow a torpid course with limited response to current treatment options. This report considers the use of the novel low-side effect profile xanomeline-trospium for the treatment of psychosis in genetic syndromes which can be more susceptible to side effects. Disclosure of Interest None Declared

Open article ↗



2024-02-20 | Neurovascular mitochondrial susceptibility impacts blood-brain barrier function and behavior

Abstract Maintenance of blood-brain barrier (BBB) integrity is critical to optimal brain function, and its impairment has been linked to multiple neurological disorders. A notable feature of the BBB is its elevated mitochondrial content compared to peripheral endothelial cells, although the functional implications of this phenomenon remain unknown. Here we studied BBB mitochondrial function in the context of the 22q11.2 deletion syndrome (22qDS), a condition associated with a highly increased risk for neuropsychiatric disease. As the 22q11.2 deletion includes 6 mitochondrial genes, and because we have previously identified BBB impairment in 22qDS, we addressed the hypothesis that mitochondrial deficits contribute to BBB dysfunction and impact behavior in this condition. We report mitochondrial impairment in human induced pluripotent stem cell (iPSC)-derived BBB endothelial cells from 22qDS patients, and in BBB endothelial cells from a mouse model of 22qDS. Remarkably, treatment to improve mitochondrial function attenuates mitochondrial deficits and enhances BBB function in both the iPSC and mouse 22qDS models. This treatment also corrected social memory in the mouse model, a deficit previously associated with BBB dysfunction. As BBB integrity correlated with social memory performance, together our findings suggest that mitochondrial dysfunction in the BBB influences barrier integrity and behavior in 22qDS.

Open article ↗



2021-05-19 | Association of Mitochondrial Biogenesis With Variable Penetrance of Schizophrenia

Discovery of mechanisms that underlie variable penetrance for neuropsychiatric illness in the context of genetic variants that carry elevated risk can advance novel treatment approaches for these disorders.To test the hypothesis that mitochondrial compensation is associated with the variable penetrance of schizophrenia in the 22q11.2 deletion syndrome (22q11DS).This case-control study compared measures of mitochondrial function and the expression of related genes in 14 induced pluripotent stem cell-derived neurons from typically developing control individuals (6 lines) and from adults with 22q11DS (8 lines). The individuals with 22q11DS included 2 groups, those carrying a diagnosis of schizophrenia and those without this diagnosis (4 lines each). Similar measures were made of lymphoblastic cells lines (LCLs) from a separate group of adults with 22q11DS with (10 lines) or without (8 lines) schizophrenia. The study included samples derived from a clinical setting. The induced pluripotent stem cell lines were derived from individuals with 22q11DS with or without a diagnosis of schizophrenia at Stanford University. The LCLs were from adults within the 22q and You Center at the Children's Hospital of Philadelphia. Data were analyzed between July 1, 2019, and January 24, 2021.Total adenosine triphosphate (ATP), oxidative phosphorylation (OXPHOS) complex activity, and messenger RNA expression via reverse transcription-polymerase chain reaction of selected genes encoding for mitochondrial proteins.Study participants included men and women aged 18 to 37 years. Of 32 participants, the mean (SD) age of men was 27 (1.9) years and of women was 29 (1.2) years. Replicating a previous study, neurons from the 22q11DS and schizophrenia (22q+Sz) group had reduced ATP levels (mean [SD], 15.6 [1.5] vs 21.9 [1.4]; P = .02) and reduced OXPHOS activity (ie, complex I; 1.51 [0.1] vs 1.89 [0.1]; P = .01). These deficits were not present in neurons from individuals with 22q11DS without schizophrenia (22q[-]Sz). In this group, the expression of multiple genes encoding OXPHOS subunits was significantly upregulated. For example, compared with control individuals, NDUFV2 expression was increased by 50% in the 22q(-)Sz group (P < .001) but not significantly changed in the 22q+Sz group. Expression of genes driving mitochondrial biogenesis, including PGC1α, showed a similar pattern of upregulation in the 22q(-)Sz group compared with the control and the 22q+Sz groups. Stimulation of mitochondrial biogenesis normalizes the ATP deficit seen in 22q+Sz neurons. Finally, using LCLs from a separate group of adults with 22q11DS, evidence for enhanced mitochondrial biogenesis was again found in the 22q(-)Sz group.In this study, an increase in mitochondrial biogenesis and function was associated with the absence of schizophrenia in neurons and LCLs from individuals with 22q11DS, but the deficit in the 22q+Sz group was reversible by agents that enhance mitochondrial biogenesis. Enhancement of mitochondrial biogenesis may provide a targetable opportunity for treatment or prevention of this disorder in individuals with 22q11DS.

Open article ↗



2021-05-12 | Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study

Abstract Dopaminergic dysregulation is one of the leading hypotheses for the pathoetiology underlying psychotic disorders such as schizophrenia. Molecular imaging studies have shown increased striatal dopamine synthesis capacity (DSC) in schizophrenia and people in the prodrome of psychosis. However, it is unclear if genetic risk for psychosis is associated with altered DSC. To investigate this, we recruited healthy controls and two antipsychotic naive groups of individuals with copy number variants, one with a genetic deletion at chromosome 22q11.2, and the other with a duplication at the same locus, who are at increased and decreased risk for psychosis, respectively. Fifty-nine individuals (21 with 22q11.2 deletion, 12 with the reciprocal duplication and 26 healthy controls) received clinical measures and [18F]-DOPA PET imaging to index striatal Ki cer . There was an inverse linear effect of copy number variant number on striatal Ki cer value ( B = −1.2 × 10 −3 , SE = 2 × 10 −4 , p < 0.001), with controls showing levels intermediate between the two variant groups. Striatal Ki cer was significantly higher in the 22q11.2 deletion group compared to the healthy control ( p < 0.001, Cohen’s d = 1.44) and 22q11.2 duplication ( p < 0.001, Cohen’s d = 2) groups. Moreover, Ki cer was positively correlated with the severity of psychosis-risk symptoms ( B = 730.5, SE = 310.2, p < 0.05) and increased over time in the subject who went on to develop psychosis, but was not associated with anxiety or depressive symptoms. Our findings suggest that genetic risk for psychosis is associated with dopaminergic dysfunction and identify dopamine synthesis as a potential target for treatment or prevention of psychosis in 22q11.2 deletion carriers.

Open article ↗



2019-05-28 | Modeling and Predicting Developmental Trajectories of Neuropsychiatric Dimensions Associated With Copy Number Variations

Abstract Copy number variants, such as duplications and hemizygous deletions at chromosomal loci of up to a few million base pairs, are highly associated with psychiatric disorders. Hemizygous deletions at human chromosome 22q11.2 were found to be associated with elevated instances of schizophrenia and autism spectrum disorder in 1992 and 2002, respectively. Following these discoveries, many mouse models have been developed and tested to analyze the effects of gene dose alterations in small chromosomal segments and single genes of 22q11.2. Despite several limitations to modeling mental illness in mice, mouse models have identified several genes on 22q11.2—Tbx1, Dgcr8, Comt, Sept5, and Prodh—that contribute to dimensions of autism spectrum disorder and schizophrenia, including working memory, social communication and interaction, and sensorimotor gating. Mouse studies have identified that heterozygous deletion of Tbx1 results in defective social communication during the neonatal period and social interaction deficits during adolescence/adulthood. Overexpression of Tbx1 or Comt in adult neural progenitor cells in the hippocampus delays the developmental maturation of working memory capacity. Collectively, mouse models of variants of these 4 genes have revealed several potential neuronal mechanisms underlying various aspects of psychiatric disorders, including adult neurogenesis, microRNA processing, catecholamine metabolism, and synaptic transmission. The validity of the mouse data would be ultimately tested when therapies or drugs based on such potential mechanisms are applied to humans.

Open article ↗



oligonucleotides
2026-06-01 | Chromosomal abnormalities and pregnancy outcomes in 350 pregnancies with prenatally diagnosed aberrant right subclavian artery: a phenotype-based retrospective cohort study

Aberrant right subclavian artery (ARSA) is the most frequent aortic-arch branching variant on prenatal sonography, and its clinical relevance is governed by the phenotypic context in which it is detected. Genotype–phenotype interpretation remains complicated by uneven genetic testing uptake and the additional anomaly burden carried in non-isolated cases. This retrospective single-center cohort comprised 350 singleton pregnancies in which ARSA was diagnosed prenatally at a tertiary perinatology center between January 2020 and April 2025. Cases were classified as isolated ARSA (n = 200), ARSA with soft markers (n = 80), or non-isolated ARSA (n = 70). The primary outcome was chromosomal abnormalities, reported with explicit denominator separation: whole-cohort prevalence and diagnostic yield among invasively tested fetuses. The 22q11.2 deletion case definition required dual confirmation by FISH and chromosomal microarray analysis (CMA). Marker- and anomaly-specific yields were examined to identify findings most strongly linked to chromosomal and adverse pregnancy outcomes. Genetic evaluation acceptance varied by phenotype (75.0% isolated, 92.5% soft markers, 92.9% non-isolated; p < 0.001). Whole-cohort chromosomal-abnormality prevalence was 4.5%, 17.5%, and 32.9%; diagnostic yield among invasively tested fetuses was 6.0%, 18.9%, and 35.4%. Trisomy 21 was the most frequent abnormality across phenotypes. Five 22q11.2 deletions (1/1/3 across phenotypes) fulfilled the dual-confirmation criteria; all three non-isolated 22q11.2 cases harbored a conotruncal cardiac anomaly. Marker co-occurrence (≥2 markers, 43.8% of soft-markers) and concurrent major anomalies (≥2, 44.3% of non-isolated) drove yield. Live-birth rates were 97.5%, 87.5%, and 71.4% (p < 0.001). On multivariable logistic regression, ARSA with soft markers (adjusted OR 4.52; 95% CI 1.86–10.96) and non-isolated ARSA (adjusted OR 10.51; 95% CI 4.52–24.44) remained independent predictors of chromosomal abnormality (optimism-corrected AUC 0.708). A compound phenotype (major anomaly + ≥2 soft markers) was present in 25.7% of non-isolated fetuses. Phenotype-based classification of prenatal ARSA reveals a significant risk gradient for chromosomal abnormality and adverse pregnancy outcome, with co-occurring markers and conotruncal anomalies emerging as the strongest individual signals. The findings support risk-concordant counseling: conservative invasive testing in confirmed isolated ARSA, intensified evaluation when soft markers co-occur, and a compound-phenotype-aware, anatomy-directed approach, including CMA and 22q11.2-targeted testing for conotruncal lesions, in the non-isolated subgroup.

Open article ↗



2025-05-27 | An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome.

Adults and children with the 22q11.2 Deletion Syndrome demonstrate cognitive, social, and emotional impairments and high risk for schizophrenia. Work in mouse model of the 22q11.2 deletion provided compelling evidence for abnormal expression and processing of microRNAs. A major transcriptional effect of the microRNA dysregulation is upregulation of Emc10, a component of the ER membrane complex, which promotes membrane insertion of a subset of polytopic and tail-anchored membrane proteins. We previously uncovered a key contribution of EMC10 in mediating the behavioral phenotypes observed in 22q11.2 deletion mouse models. Here, we show that expression and processing of miRNAs is abnormal and EMC10 expression is elevated in neurons derived from 22q11.2 deletion carriers. Reduction of EMC10 levels restores defects in neurite outgrowth and calcium signaling in patient neurons. Furthermore, antisense oligonucleotide administration and normalization of Emc10 in the adult mouse brain not only alleviates cognitive deficits in social and spatial memory but remarkably sustains these improvements for over 2 months post-injection, indicating its therapeutic potential. Broadly, our study integrates findings from both animal models and human neurons to elucidate the translational potential of modulating EMC10 levels and downstream targets as a specific venue to ameliorate disease progression in 22q11.2 Deletion Syndrome.

Open article ↗



2024-05-03 | DGCR8 haploinsufficiency leads to primate-specific RNA dysregulation and pluripotency defects

The 22q11.2 deletion syndrome (22qDS) is caused by a microdeletion in chromosome 22, including DGCR8, an essential gene for miRNA production. The contribution of human DGCR8 hemizygosity to the disease is still unclear. In this study, we generated two human pluripotent cell models containing a single functional DGCR8 allele to elucidate its role on 22qDS. DGCR8+/- cells show increased apoptosis as well as self-renewal and differentiation defects in both the naive and primed states. The expression of primate-specific miRNAs was largely affected, due to impaired miRNA processing and chromatin accessibility. DGCR8+/- cells also displayed a pronounced reduction in human endogenous retrovirus class H (HERVH) expression, a primate-specific retroelement essential for pluripotency maintenance. Importantly, the reintroduction of primate-specific miRNAs as well as the miR-371-3 cluster rescued the cellular and molecular phenotypes of DGCR8+/- cells. Our results suggest that DGCR8 is haploinsufficient in humans and that miRNAs and transposable elements may have co-evolved in primates as part of an essential regulatory network to maintain stem cell identity.

Open article ↗



2024-01-21 | 194 Fetal fraction amplification dramatically increases PPV for 22q11.2 deletion syndrome in prenatal cell-free DNA screening

22q11.2 deletion syndrome occurs in approximately 1 in 2,000-4,000 births. Prenatal cell-free DNA screening (pcfDNA) can detect fetuses affected by deletions as small as 2.5 Mb. Fetal fraction amplification (FFA), which has been shown to yield an average fetal fraction (FF) in excess of 20%, may further enhance pcfDNA detection of these deletions. Positive predictive values (PPV) of pcfDNA screening for 22q11.2 microdeletion have been reported between 20%-50%. Here, we sought to describe the impact of FFA on the PPV of 22q11.2 microdeletion screening using a whole-genome sequencing (WGS)-based pcfDNA platform. We retrospectively analyzed data from patients who underwent WGS-based pcfDNA screening with FFA (Prequel™, Myriad Genetics, Inc.) between 8/20-10/22. For screen-positive cases, pregnancy outcome data were requested via a routine HIPAA-compliant process. All samples with diagnostic confirmation were used to calculate PPV, defined as: true positives/(true positives + false positives). Confidence interval (CI) was estimated using the Exact Binomial Test. Complete outcomes were obtained for 54 cases that screened positive for 22q11.2 microdeletion; 21 underwent molecular diagnostic testing. All 21 were confirmed as true positives, for a PPV of 100% (21/21; 95% CI 83.9%-100%). Among the 33 cases that declined molecular confirmation, 17 had ultrasound findings that are either strongly or moderately associated with 22q11.2 deletion syndrome (e.g., cardiac defects, polyhydramnios, skeletal defects, intrauterine growth restriction). The average FF of true positive samples was 23.0%. For screen-positive patients who declined diagnostic testing, the average FF was 21.6%. The increased FF levels conferred by FFA yield a PPV for 22q11.2 microdeletion higher than any previous studies have reported, and comparable to that for common autosomal trisomies. Because respective FF levels were comparable in patients with and without diagnostic confirmation, PPV is likely to be comparable in patients with and without diagnostic confirmation.

Open article ↗



2021-05-10 | Long Noncoding RNA lnc-TSSK2-8 Activates Canonical Wnt/β-Catenin Signaling Through Small Heat Shock Proteins HSPA6 and CRYAB

Congenital heart defects (CHDs) are the most common birth defects worldwide. 22q11.2 deletion syndrome is the most common microdeletion disorder that has been frequently associated with conotruncal malformations. By now, the dosage-sensitive gene TBX1 has been adopted as the major pathogenic gene responsible for 22q11.2 deletion, which is regulated by canonical Wnt/β-catenin signaling pathway in heart outflow tract development. Here, we report the long noncoding RNA (lncRNA) lnc-TSSK2-8, which is encompassed in the 22q11.2 region, that can activate canonical Wnt/β-catenin signaling by protecting β-catenin from degradation, which could result from decreased ubiquitination. Such effects were mediated by two short heat shock proteins HSPA6 and α-β-crystallin (CRYAB), whose expression was regulated by lnc-TSSK2-8 through a competing endogenous RNA (ceRNA) mechanism. In clinical practice, the pathogenesis of copy number variation (CNV) was always attributed to haploinsufficiency of protein-coding genes. Here, we report that the 22q11.2 lncRNA lnc-TSSK2-8 significantly activated canonical Wnt/β-catenin signaling, which has major roles in cardiac outflow tract development and should act upstream of TBX1. Our results suggested that lncRNAs should contribute to the etiology of CNV-related CHD.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.